UNSPSC 51241513: Brimonidine/timolol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP105. This VA Drug Class (OP105) classifies this compound as belonging to the group ANTIGLAUCOMA COMBINATIONS, TOPICAL OPHTHALMIC.

UNSPSC 51241513 Brimonidine/timolol is a Commodity code for a combination ophthalmic medication used to lower intraocular pressure in glaucoma and ocular hypertension treatment. State and local governments procure this drug primarily through health departments, correctional facilities, and public hospital systems for inmate and indigent patient populations. The medication combines an alpha-2 adrenergic agonist (brimonidine) and a non-selective beta-blocker (timolol) in fixed-dose formulations, typically supplied as eye drops. Purchasing bodies treat this as a line-item pharmaceutical acquisition within broader pharmacy inventory management and compliance with formulary protocols, often bundled with other glaucoma agents or managed through group purchasing agreements with pharmaceutical distributors.

The source provided contains no recent state and local contract opportunities tagged to this code, making it impossible to characterize current geographic activity, issuing-body concentration, or representative solicitations. The code appears to represent a low-volume or internally managed pharmaceutical line item within existing health-system contracts rather than a standalone procurement vehicle. Without recent RFP, RFQ, IFB, or ITB notices in the source block, no actionable market intelligence is available to inform pursuit strategy at this time.